选择性CDK2抑制剂INX-315在固体瘤中诱导细胞周期停止和衰老
Catherine Dietrich1,2, Alec Trub3, Antonio Ahn1,2
1Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Cancer discovery
|December 4, 2023
概括
一种新药物INX-315可选择性抑制循环素依赖激酶2 (CDK2),显示出治疗CCNE1增强癌症和克服乳腺癌中对CDK4/6抑制剂的耐药性的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环素依赖激酶2 (CDK2) 与CCNE1增强癌症的扩散以及乳腺癌中对CDK4/6抑制剂 (CDK4/6i) 的获得性耐药性有关.
- 由于缺乏选择性抑制剂,CDK2抑制的治疗潜力受到限制.
研究的目的:
- 评估INX-315的疗效和作用机制,一种新的选择性CDK2抑制剂.
- 评估INX-315在CCNE1放大瘤和CDK4/6i耐药乳腺癌模型中的潜力.
主要方法:
- 使用基于细胞的测定,患者衍生异种移植 (PDX) 和转基因小鼠模型进行临床前评估.
- 评估视网膜母细胞瘤蛋白酸化,治疗诱导衰老 (TIS),细胞周期控制和E2F目标抑制.
主要成果:
- INX-315证明了对CDK2.2的强大和选择性抑制.
- 在CCNE1增强瘤中,INX-315诱导了视网膜母细胞瘤蛋白和TIS的低酸化,导致了持久的瘤生长控制.
- 在乳腺癌中,INX-315通过恢复细胞循环控制和通过增强的E2F标抑制延迟抵抗的出现,克服了CDK4/6i耐药性.
结论:
- 用INX-315选择性抑制CDK2在CCNE1增强癌症和CDK4/6i抗性乳腺癌中显示出显著的临床前活性.
- INX-315诱导细胞循环停止和衰老表型,支持其临床发展.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


